- Home
- PTGX vs NVCR Comparison
PTGX vs NVCR Comparison
Compare PTGX & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTGX | NVCR |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | 1488 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 1.5B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PTGX | NVCR |
|---|---|---|
| Price | $94.47 | $13.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $88.33 | $28.42 |
| AVG Volume (30 Days) | 953.6K | ★ 1.8M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.72 | N/A |
| Revenue | $209,217,000.00 | ★ $642,269,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $296.47 | $5.62 |
| P/E Ratio | $132.39 | ★ N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $33.70 | $10.70 |
| 52 Week High | $95.39 | $34.13 |
Technical Indicators
Market Signals| Indicator | PTGX | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 70.99 | 60.37 |
| Support Level | $88.30 | $10.79 |
| Resistance Level | $92.80 | $13.94 |
| Average True Range (ATR) | 2.82 | 0.61 |
| MACD | 0.19 | 0.22 |
| Stochastic Oscillator | 94.19 | 80.48 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.